Martin Mackay

Latest Headlines

Latest Headlines

Biopharma's 10 highest-paid heads of R&D

The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.

Science pays: 2013's 10 best-compensated R&D chiefs in biopharma

For an idea of what kind of year a drug developer had, take a look at what it paid its head of R&D. Click through our roundup for a look at who ranks where in the biopharma R&D world. Read more >>

Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout

The biotech has struck a deal with little Prothelia and the University of Nevada, Reno, where it will step in and conduct development research on a protein replacement therapy for merosin-deficient congenital muscular dystrophy, or MDC1A.

Buzz: Why is Roche considering a big buyout of Alexion?

Shares of the rare disease drug specialist Alexion spiked 18% this afternoon after Bloomberg reported that Roche has been putting out feelers to raise cash for a big buyout. The spike put Alexion's market cap at $23 billion, up $3 billion, making this potentially the biggest proposed deal of the year, dwarfing Amgen's $10 billion play for Onyx.

Buzz: AstraZeneca reorganization inspires fresh rumors of Shire bid

Over the past 10 years Shire has become a business model in the biotech world. It's added impressive new units to the company, built sales with new products and enjoyed high status in the red-hot field of rare diseases. And in this business at this time, what's admired is generally a topic of takeover rumors.

AstraZeneca research chief Mackay ousted in executive shakeup

The new CEO at AstraZeneca has put together his top executive crew responsible for turning around the laggard pharma giant. And there was no room on board for R&D chief Martin Mackay. A little more than two years since he was poached from Pfizer, Pascal Soriot is eliminating the position of president of R&D while also bidding goodbye to Tony Zook and the now-extinct job of EVP, global commercial.

Hungry AstraZeneca teams with Ironwood on $150M China drug deal

The deal pairs the company on the research work that needs to be done in China to win an approval for irritable bowel syndrome, with the biotech company relentlessly hanging on to a 50% share of the profits in China.

AstraZeneca turns to Beijing CRO as it scrambles to repair damaged pipeline

After chopping deep into its R&D operations to scale back on expenses, AstraZeneca has struck a pact to outsource part of its drug discovery operations to a CRO in China. Pharmaron, which only recently snipped the ribbon at its new complex in Beijing, will play a supporting role on chemistry, drug metabolism and pharmacokinetics, and efficacy screening for the pharma giant in a multi-year deal announced over the weekend.

AstraZeneca pulls the plug on sepsis drug after trial tanks

Add another failure in AstraZeneca's pipeline. The London-based drug giant and partner BTG have scrapped development of an experimental antibody for sepsis and septic shock after mid-stage study bombed, BTG announced today.

AZ's MedImmune axing 200 in California R&D restructuring

AstraZeneca's biotech arm, MedImmune, is doing its part in a corporate restructuring operation--axing 200 workers and relocating 100 others as it shutters a pair of facilities in California.